Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Robotic therapy animals could open new doors for trauma recovery, autism support, and mental health care at scale.

Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on ...

A New Jersey biotech company has paused a gene therapy trial after a participant had an unexpected adverse event and later died from a sudden, severe infection.  Rocket Pharmaceuticals said the ...

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease: Cranbury, New Jersey Wednesday, May 28, 2025, 14:00 Hrs [IST] Rocket P ...

CRANBURY, NJ, USA I May 27, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has suspended dosing in its Danon disease gene therapy trial after a patient ...